Three-part, in-depth analysis of biopharma investments in
obesity medications highlights potential impact on patient
population historically faced with limited options
LONDON, Oct. 24,
2023 /PRNewswire/ -- BioWorld™ published
by Clarivate Plc (NYSE:CLVT), a global leader in
connecting people and organizations to intelligence they can trust
to transform their world, examines the impact of emerging
obesity medicines in a new three-part series, The Rise of Obesity.
The special coverage offers in-depth analysis of how the
anticipated multibillion-dollar market potential for obesity
medications in the coming years will impact biopharma, insurance
companies and a patient population in need of safer options.
The increasing prevalence of obesity across the world is driving
interest among investors to be a part of a movement that is poised
to change the health care paradigm. Emerging medicines including
glucagon-like peptide 1 (GLP-1) receptor agonists and drugs with
other mechanisms of action are increasingly shown to have benefits
beyond weight loss.
Over $1 billion of investment is
anticipated in obesity through licensing or M&As in
2023,1 with the overall market expected to climb upwards
of $50 billion in the coming years.
The result of such growth could include significant savings in
treating obese and overweight conditions, as well as the
comorbidities associated with them. Novo Nordisk recently reported
sales of Wegovy totalling $1.7
billion for the first half of 2023, up 367% over the prior
year.2 Sales of Ozempic, a lower-dose version of
semaglutide, are up 58% year over year.3 The significant
rise in sales reinforces the meteoric rise of obesity drugs -
profits of which can help drive drug development to further benefit
patients and business stakeholders alike.
Karen Carey, BioWorld Managing
Editor and Senior Analyst, explores the challenges and the
opportunity of advancing obesity medications, in three in-depth
features, including:
- With high societal costs, a burgeoning market size,
developers seek reimbursement for weight-loss meds
The multibillion-dollar market potential for obesity medications
that analysts expect in the next decade signifies change is coming
for a patient population historically plagued with unsafe options
and generally dismissed by investors and insurers.
- Development, investments, partnerships climb, but safety is
key
The ability of obesity medications to impact
co-morbidities, reducing the symptoms and costs associated with
down-the-road disease, has attracted significant attention
throughout the biopharma industry.
- Biopharmas focus on glucagon, amylin and other targets
beyond GLP-1s
Glucagon-like peptide 1 receptor agonists have
brought significant weight loss to patients, catching the attention
of investors, but drug developers are continually seeking new
therapies with different mechanisms to enhance the effects and
improve the tolerability.
Lynn Yoffee, Publisher, BioWorld, said: "Drug-induced weight
loss has finally matured into a viable therapeutic option. But the
reality of drug development is not just proof that they work. There
must be a way to bring expensive drugs to patient populations,
which is why BioWorld examined drugmakers' efforts to obtain
reimbursement – tantamount to treating most patients – and the
behind-the-scenes dealmaking and investments to broaden access. The
BioWorld special report highlights the vast new market for drugs
for obesity that will have major impacts on overall health since
reducing weight is associated with reducing co-morbidities and
costs associated with down-the-road diseases."
For more exclusive in-depth coverage of obesity and metabolic
health on BioWorld, visit here.
Join the conversation and mention BioWorld
on Twitter and LinkedIn as well as Clarivate
for Life Sciences & Healthcare
on Twitter and LinkedIn.
About BioWorld
With writers and editors stationed around the globe, BioWorld
published by Clarivate, reports the breaking news - and provides
key perspective on hundreds of therapeutics and devices in
development, the companies behind those candidates, the business
development transactions that evolve the markets, and the
regulatory hurdles that both challenge and guard the processes.
BioWorld has a long tradition of excellence in journalism.
Collectively, the news services have been honored with 61 awards
dating back to 1998.
About Clarivate
Clarivate™ is a leading global information services provider. We
connect people and organizations to intelligence they can trust to
transform their perspective, their work and our world. Our
subscription and technology-based solutions are coupled with deep
domain expertise and cover the areas of Academia & Government,
Life Sciences & Healthcare and Intellectual Property. For more
information, please visit www.clarivate.com.
Media contact:
Catherine Daniel
Director External Communications, Life Sciences &
Healthcare
newsroom@clarivate.com
|
|
|
|
|
|
1
|
Sources: BioWorld,
CDC, Cortellis, NCBI, NLM, Morgan Stanley Research
|
2
|
Source:
BioWorld
|
3
|
Source:
BioWorld
|
View original
content:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-examines-impact-of-emerging-medicines-on-obesity-301964656.html
SOURCE Clarivate Plc